Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
05/2003
05/02/2003EP0724387B1 Angiotension ii receptor antagonists for the treatment of chronic anti-inflammatory diseases
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2411009A1 Heterocyclo-alkylsulfonyl pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035898A1 Method of screening drug acting on cell wall
05/01/2003WO2003035876A1 Use of a double strand ribonucleic acid for treating an infection with a positive-strand rna-virus
05/01/2003WO2003035835A2 Glycoprotein compositions
05/01/2003WO2003035696A2 Humanized antibodies against icam-1, their production and uses
05/01/2003WO2003035687A1 Nogo receptor homologues and their use
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035681A2 Mycobacterial genes down-regulated during latency
05/01/2003WO2003035679A2 Molecules
05/01/2003WO2003035676A1 Groel chimeric protein and vaccine
05/01/2003WO2003035650A1 Entry inhibitor
05/01/2003WO2003035648A1 Aryl substituted oxazolidinones with antibacterial activity
05/01/2003WO2003035638A1 4-imidazolin-2-one compounds
05/01/2003WO2003035627A1 Piperazine derivatives with ccr1 receptor antagonist activity
05/01/2003WO2003035626A2 Azole derivatives and pharmaceutical compositions containing them
05/01/2003WO2003035177A2 Optimal polymer mixtures for gastric retentive tablets
05/01/2003WO2003035137A2 Method and apparatus for dispensing inhalator medicament
05/01/2003WO2003035109A1 Remedies for pruritus
05/01/2003WO2003035106A1 Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
05/01/2003WO2003035102A1 Use of egf to inhibit pathogenic infections of the urogenital tract
05/01/2003WO2003035100A1 Neuropilin as a novel therapeutic target for modulation of immune reponses
05/01/2003WO2003035097A1 A method for identification and development of therapeutic agents
05/01/2003WO2003035089A1 Preventives/remedies for foot and mouth disease
05/01/2003WO2003035079A1 A combination product comprising melagatran and dexamethasone
05/01/2003WO2003035077A1 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
05/01/2003WO2003035076A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
05/01/2003WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
05/01/2003WO2003035073A1 Isoxazoline derivatives useful as antimicrobials
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035064A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
05/01/2003WO2003035060A1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
05/01/2003WO2003035058A2 Polymaleide compounds and their medical use
05/01/2003WO2003035057A1 Inhibitors of dipeptidyl peptidase iv
05/01/2003WO2003035056A1 Combination of liponic acid and glutamine in food and pharmaceutical products
05/01/2003WO2003035052A1 Preventives/remedies for viral infection
05/01/2003WO2003035050A2 Use of tyrosine kinase inhibitors for promoting hair growth
05/01/2003WO2003035049A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
05/01/2003WO2003035041A1 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
05/01/2003WO2003035036A1 Montelukast granule formulation
05/01/2003WO2003035012A2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003WO2003035004A2 Immunotherapy for reversing immune suppression
05/01/2003WO2003035001A2 Anti-hsv agent for inhibiting replication of hsv-1 and hsv-2 and method of producing a substance having anti-hsv activity
05/01/2003WO2003034988A2 Injectable compositions for the controlled delivery of pharmacologically active compound
05/01/2003WO2003034981A2 Prevention of recurrent viral disease
05/01/2003WO2003034903A2 Psma antibodies and protein multimers
05/01/2003WO2003011223A3 Immunomodulatory compounds and methods of use thereof
05/01/2003WO2003002152A3 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
05/01/2003WO2003000277A3 Antimicrobial peptides
05/01/2003WO2002100351A3 A method for treating inflammatory diseases by administering a ppar-delta agonist
05/01/2003WO2002100336A3 Tissue-specific endothelial membrane proteins
05/01/2003WO2002090553A3 Recombinant fusion proteins and the trimers thereof
05/01/2003WO2002090352A3 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
05/01/2003WO2002089835A3 Pharmaceutical dosage form of amorphous nelfinavir mesylate
05/01/2003WO2002083712A3 Transporters and ion channels
05/01/2003WO2002081478A3 Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
05/01/2003WO2002079186A3 Aminopiperidine derivatives as modulators of chemokine receptor activity
05/01/2003WO2002078634A3 Methods for using kdop and kdop synthase inhibitors for the treatment of bacterial infection
05/01/2003WO2002076483A3 Bacteriophage preparation
05/01/2003WO2002076391A3 Microbial feeds for aquaculture and agriculture
05/01/2003WO2002074806A3 New interferon beta-like molecules
05/01/2003WO2002074292A3 Hormone replacement therapy
05/01/2003WO2002074287A3 Antibacterial compositions containing of oxapenem-3-carboxylic acids and antibiotics
05/01/2003WO2002072581A3 Pyrazolopyriadine derivatives
05/01/2003WO2002062378A3 Hyperblebbing bacterial strains and use thereof for production of vaccines
05/01/2003WO2002060458A3 Compositions and method of tissue superoxygenation
05/01/2003WO2002049633A3 Use of amidoamines to treat or prevent acanthamoeba and fungal infections
05/01/2003WO2002049627A3 Antifungal compositions containing an antibiotic and one or more amidoamines
05/01/2003WO2002048165A3 Antiviral agents for treatment of flaviviridae infections
05/01/2003WO2002048148A3 Pyrazolopyridine derivatives
05/01/2003WO2002046158A9 Piperidine/piperazine-type inhibitors of p38 kinase
05/01/2003WO2002045741A3 Helicobacter pylori prime and boost vaccination comprising caga and nap antigens
05/01/2003WO2002026250A3 Vaccines for proliferative ileitis
05/01/2003WO2002022851A3 Novel tumor-associated marker
05/01/2003WO2001066572A3 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof
05/01/2003US20030084471 Methods and compositions for RNA interference
05/01/2003US20030083610 Compositions and method of tissue superoxygenation
05/01/2003US20030083500 Imidazonaphthyridines
05/01/2003US20030083466 cDNA clone MY1 that encodes a novel human 7-transmembrane receptor
05/01/2003US20030083385 Such as 1-(5-(2-(5-chloro-2-methoxybenzamido)ethyl)-2-(2-methoxyethoxy) -(phenylsulfonyl)-3-methylthiourea; treating cardiovascular disorders
05/01/2003US20030083369 Pyranocoumarin compounds as a novel pharmacophore with anti-TB activity
05/01/2003US20030083363 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
05/01/2003US20030083362 Synthesis and antimicrobial activity of novel dicationic"reversed amidines"
05/01/2003US20030083347 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/01/2003US20030083335 CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP)
05/01/2003US20030083333 1,4-Disubstituted benzo-fused compounds
05/01/2003US20030083308 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and DNA viruses
05/01/2003US20030083307 Anti-HCV nucleoside derivatives
05/01/2003US20030083296 Antisense modulation of caspase 8 expression
05/01/2003US20030083286 Comprises penetration enhancer (fatty acid); drug delivery; increases bioavailability of oligonucleotides
05/01/2003US20030083272 Sense mrna therapy
05/01/2003US20030083270 Process for the production of (-)-epigallocatechin gallate
05/01/2003US20030083268 Isoquinoline compounds having antiinfective activity
05/01/2003US20030083256 Compositions and methods for enhancing drug delivery across and into epithelial tissues
05/01/2003US20030083254 Heparanase-like proteins and nucleotides that encode them
05/01/2003US20030083242 Methods and compositions for treating or preventing peripheral neuropathies
1 ... 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 ... 1798